Categories Earnings, Retail

Barnes & Noble trims loss in Q2

Barnes & Noble (BKS) trimmed down its loss in the second quarter of 2019 with a year-over-year drop in sales. The bookseller’s loss stood at $27.4 million, or $0.38 per share compared to a loss of $30.1 million, or $0.41 per share in the prior year quarter. Revenue declined 2.5% to $771 million, while comp store sales decreased 1.4%.

Barnes & Noble second quarter 2019 Earnings Infographic

Once the book-selling juggernaut Barnes & Noble announced last month that the board is exploring options after it has got inquiries from various firms to acquire the retailer. The potential parties that showed interest in taking over the company included its current Chairman Leonard Riggio.

“While we cannot predict the outcome of the holiday, we are putting our full effort behind our holiday plans, including launching a new ad campaign. We expect this to lead to continued sales improvement during the holiday period,” said Leonard Riggio.

For fiscal 2019, Barnes & Noble continues to expect EBITDA to be in a range of $175 million to $200 million, excluding unusual or non-recurring items.

Earlier in July, the company axed its CEO Demos Parneros, who didn’t even complete one year as the bookseller’s CEO. In August, Parneros filed a case against the company, mainly alleging its Chairman Riggio. Then, the company came out with the reasons for terminating Parneros and accused him of sexual harassment and violating other company policies.

Barnes & Noble surges above 20%; board to explore sale

The New York-based company’s shares closed down 2.31% at $6.76 on Monday and were down 2.5% when the market opened today. The stock dropped 1% in the year-to-date period, while declining 9% in the past 52-weeks.

 

Get access to timely and accurate verbatim transcripts that are published within hours of the event

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top